Cross-resistance in the 2′,2′-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs

This publication has 37 references indexed in Scilit:

• Mechanisms of drug resistance in ovarian cancer
  Cancer, 2010
• Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562
  British Journal of Haematology, 1999
• Postconfluent multilayered cell line cultures for selective screening of gemcitabine
  European Journal Of Cancer, 1998
• Leading Article: Oncologic, Endocrine & Metabolic: New antimetabolites in preclinical and clinical development
  Expert Opinion on Investigational Drugs, 1996
• Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer Patients
  JNCI Journal of the National Cancer Institute, 1994
• New targets for pyrimidine antimetabolites for the treatment of solid tumours
  Pharmacy World & Science, 1994
• Cancer of the Ovary
  New England Journal of Medicine, 1993
• 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines
  Biochemical Pharmacology, 1993
• The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer
  British Journal of Cancer, 1993
• New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
  JNCI Journal of the National Cancer Institute, 1990